SCHEMBL3758242

SCHEMBL3758242

CCCCCCCCCCCCCCCC(=O)N[C@H]([C]=O)CCCCN

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 3/20 0.55
DNM1 Q05193 1/20 0.53
FAAH O00519 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPK1 P28482 1/20 0.50
NOD1 Q9Y239 3/20 0.46
PLA2G2C Q5R387 1/20 0.46
GNAI3 P08754 1/20 0.44
GNAO1 P09471 1/20 0.44
GNAI1 P63096 1/20 0.44
SIRT6 Q8N6T7 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
PLA2G10 O15496 2/20 0.43
TLR2 O60603 1/20 0.43
HSP90AA1 P07900 1/20 0.42
PLA2G4A P47712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8846585 1.00 SLC6A5 (0.55) SLC6A5DNM1FAAHMEN1KMT2A
SCHEMBL7186702 0.98 SLC6A5 (0.53) SLC6A5DNM1FAAHMEN1KMT2A
SCHEMBL3717425 0.92 SLC6A5 (0.45) SLC6A5DNM1FAAHMEN1KMT2A
SCHEMBL27535723 0.92 SLC6A5 (0.45) SLC6A5DNM1FAAHMEN1KMT2A
SCHEMBL2182070 0.88 SLC6A5 (0.40) SLC6A5DNM1MEN1KMT2A
SCHEMBL3976246 0.87 LMNA (0.52) SLC6A5MEN1KMT2APLA2G2CPLA2G10
SCHEMBL10577267 0.85 SLC6A5 (0.60) SLC6A5FAAHMEN1KMT2A
SCHEMBL21724596 0.84 FAAH (0.51) SLC6A5DNM1FAAHMEN1KMT2A
SCHEMBL21724553 0.84 FAAH (0.51) SLC6A5DNM1FAAHMEN1KMT2A
SCHEMBL21724212 0.84 FAAH (0.51) SLC6A5DNM1FAAHMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551956-B2 Compositions containing peptides with non-natural amino acids and methods of use AVON PRODUCTS, INC. (US) 2013-10-08 US disclosed
EP-2398489-A2 COMPOSITION COMPRISING N2 - (1-OXOHEXADECYL) - LYSYL - VALYL - LYSINE FOR TREATING ROSACEA AND ITS SYMPTOMS DSM IP Assets B.V. (NL) 2011-12-28 EP disclosed
WO-2010094452-A2 NOVEL COMPOSITION DSM IP ASSETS B.V. (NL) 2010-08-26 WO disclosed
US-20090082252-A1 Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use AVON PRODUCTS INC. 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082252-A1 Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use CUTA, NGLY1, LNPEP SLC6A5 3007/4885DNM1 1943/4885FAAH 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.